Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

Please provide your email address to receive an email when new articles are posted on . Pirtobrutinib significantly improved PFS for patients with CLL and SLL compared with standard chemoimmunotherapy ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed ...

Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

As a diehard enthusiast of video games, Ediz Guner has been attentively following the ebbs and flows of the gaming industry for a long period of time. This, coupled with his hobby of extensively ...

Danganronpa 2: Goodbye Despair is making a comeback in the form of Danganronpa 2x2 for PC via Steam, Nintendo Switch, Switch 2, PlayStation 5, and Xbox Series X and S. Spike Chunsoft announced a ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

Senior Lecturer of Exercise Immunology, Faculty of Health and Medical Sciences, School of Biosciences, University of Surrey CLL starts when a type of immune cell called a B cell – normally responsible ...